Pattern and Outcomes of Chest Diseases

Sponsor

Assiut University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT06053528

Collaborator

(none)

2,000

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The objective of this study is to determine the pattern and outcome of respiratory diseases in adults patients admitted to the Department of Chest Diseases at Assiut University Hospital.

Condition or Disease	Intervention/Treatment	Phase
Chest--Diseases	Drug: Antibiotic

Detailed Description

Respiratory diseases constitute an important global health burden. Pneumonia, tuberculosis, obstructive and restrictive lung diseases, pleural diseases, and malignancies are common respiratory conditions for hospital admission.Before the emergence of COVID-19, pneumonia, including community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP)/ventilation-associated pneumonia (VAP), was one of the most common infectious diseases, and could cause major health problems, associated with high morbidity and mortality in all age groups worldwide . The outbreak of COVID-19 has significantly changed the epidemiology of respiratory tract infection. More than 376 million people have been infected and 5 million have died in the whole world. This in addition to the long term post COVID pulmonary sequelae. Chronic obstructive pulmonary disease (COPD), lower respiratory tract infections, lung cancer and tuberculosis have been identified as top four respiratory diseases among ten leading causes of death worldwide. The forum of international respiratory societies (FIRS) estimated that 65 million people have moderate to severe COPD resulting in 3 million deaths per year, making it third leading cause of death worldwide .Currently, asthma affects an estimated 334 million people worldwide and is projected to increase to 400 million by the year 2025 .

In ;2015 10,4million people developed TB with 1.4 million global deaths were reported.

Neoplasms of the lungs are the leading cause of cancer incidence and mortality worldwide.

Study Design

Study Type:

Observational

Anticipated Enrollment :

2000 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Pattern and Outcome of Respiratory Diseases in Patients Admitted in the Chest Department at Assiut University Hospital

Anticipated Study Start Date :

Oct 1, 2023

Anticipated Primary Completion Date :

Oct 1, 2024

Anticipated Study Completion Date :

Dec 1, 2024

Outcome Measures

Primary Outcome Measures

Determine number of patients who experience improvement on discharge [One year]
Number of patient who Transferred to another hospital forcontintreatment [One year]
Number of patient died while on admission [One year]
Number of patient who Discharged against medical advice [One year]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 90 Years

Sexes Eligible for Study:

All

Inclusion Criteria:

All adults patients admitted to the Chest Department during the study period will be included.

Exclusion Criteria:

Patients who will die, be discharged, or be transferred before completing data collection will be excluded from our study.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Global Asthma Report [Internet]. Auckland: Global Asthma Network; 2014. Available from

Publications

None provided.

Responsible Party:

Fatma Hamdan Zaki Adeel, Resident doctor, Assiut University

ClinicalTrials.gov Identifier:

NCT06053528

Other Study ID Numbers:

Pattern of chest diseases

First Posted:

Sep 25, 2023

Last Update Posted:

Sep 25, 2023

Last Verified:

Sep 1, 2023

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Anti-Bacterial Agents

Study Results

No Results Posted as of Sep 25, 2023